Design of high-performance tumor-informed molecular residual disease (MRD) panels from low FFPE tumor input
Impact of Combinatorial Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder
High positive predictive value of 22q11.2 microdeletion screening by prenatal cell-free DNA testing that incorporates fetal fraction amplification.
Cancer Risk Assessment and Hereditary Cancer Genetic Testing in a Community OB/GYN Setting.
P675 Interrogating the Source: An Investigation of the Impact of Founder Variants on Residual Risk in Carrier Screening.
A second-generation polygenic risk score (PRS) based on genetic ancestry improves breast cancer (BC) risk prediction for all ancestries.
Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediaterisk prostate cancer
Title
Product
Journal / Conference
Year
Type
ID
Search recent publications from Myriad authors and contributors.